» Articles » PMID: 32368318

LINC00511 Promotes Gastric Cancer Cell Growth by Acting As a CeRNA

Overview
Date 2020 May 6
PMID 32368318
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Gastric cancer (GC) is one of the most aggressive malignancies, with a high incidence and poor prognosis worldwide. Recently, accumulating evidence has illustrated that long noncoding RNAs (lncRNAs) play pivotal roles in many cancers. It has been reported that LINC00511 contributes to tumorigenesis in various diseases. However, the role of LINC00511 in GC cell growth remains mostly unknown.

Aim: To determine whether the lncRNA LINC00511 exerted its carcinogenic function in GC the miR-124-3p/PDK4 axis.

Methods: Cell culture and transfection, RNA extraction and quantitative real-time PCR, CCK-8 assay, Colony formation assay, Luciferase reporter assay, RIP assay, RNA pull-down assay, and Western blot analysis were used to show expression and mechanisms of LINC00511 in GC progression and apoptosis. Rescue assays were performed to verify the relationships among LINC00511, miR-124-3p and PDK4 further.

Results: The expression of LINC00511 was remarkably upregulated in GC cells compared to that in corresponding normal cell lines. Compared to the controls, cell proliferation was inhibited, and cell apoptosis was increased upon LINC00511 knockdown, demonstrating that LINC00511 influenced GC cell growth. An exploration of the molecular mechanism revealed that LINC00511 functioned as a molecular sponge of miR-124-3p and that PDK4 was a downstream target of miR-124-3p in GC. Rescue assays showed that the overexpression of PDK4 could partly restore the inhibitory function of si-LINC00511 in GC.

Conclusion: These data demonstrate that LINC00511 promotes gastric cancer cell growth by acting as a ceRNA to regulate the miR-124-3p/PDK4 axis, which may be a promising therapeutic target for GC.

Citing Articles

The emerging roles of LINC00511 in breast cancer development and therapy.

Zhao L, Biswas S, Li Y, Sooranna S Front Oncol. 2024; 14:1429262.

PMID: 39206156 PMC: 11349568. DOI: 10.3389/fonc.2024.1429262.


Correlation analysis of disulfidptosis-related gene signatures with clinical prognosis and immunotherapy response in sarcoma.

Xu J, Guo K, Sheng X, Huang Y, Wang X, Dong J Sci Rep. 2024; 14(1):7158.

PMID: 38531930 PMC: 10966107. DOI: 10.1038/s41598-024-57594-x.


The Intergenic Type LncRNA (LINC RNA) Faces in Cancer with In Silico Scope and a Directed Lens to LINC00511: A Step toward ncRNA Precision.

Eldash S, Sanad E, Nada D, Hamdy N Noncoding RNA. 2023; 9(5).

PMID: 37888204 PMC: 10610215. DOI: 10.3390/ncrna9050058.


Unlocking the potential of non-coding RNAs in cancer research and therapy.

Uppaluri K, Challa H, Gaur A, Jain R, Krishna Vardhani K, Geddam A Transl Oncol. 2023; 35:101730.

PMID: 37406550 PMC: 10366642. DOI: 10.1016/j.tranon.2023.101730.


RNA-binding protein promotes the tumor progression of gastric cancer by binding to and regulating gastric cancer-related genes.

Wang N, Qiao H, Hao J, Deng C, Zhou N, Yang L J Gastrointest Oncol. 2023; 14(2):585-598.

PMID: 37201055 PMC: 10186516. DOI: 10.21037/jgo-23-151.


References
1.
Park S, Choi E, Bae D, Sohn H, Kim S, Kim Y . The LncRNA EPEL Promotes Lung Cancer Cell Proliferation Through E2F Target Activation. Cell Physiol Biochem. 2018; 45(3):1270-1283. DOI: 10.1159/000487460. View

2.
Ren S, Xu Y . AC016405.3, a novel long noncoding RNA, acts as a tumor suppressor through modulation of TET2 by microRNA-19a-5p sponging in glioblastoma. Cancer Sci. 2019; 110(5):1621-1632. PMC: 6500966. DOI: 10.1111/cas.14002. View

3.
DAngelo B, Benedetti E, Cimini A, Giordano A . MicroRNAs: A Puzzling Tool in Cancer Diagnostics and Therapy. Anticancer Res. 2016; 36(11):5571-5575. DOI: 10.21873/anticanres.11142. View

4.
Zeng H, Zheng R, Guo Y, Zhang S, Zou X, Wang N . Cancer survival in China, 2003-2005: a population-based study. Int J Cancer. 2014; 136(8):1921-30. DOI: 10.1002/ijc.29227. View

5.
Ding J, Yang C, Yang S . LINC00511 interacts with miR-765 and modulates tongue squamous cell carcinoma progression by targeting LAMC2. J Oral Pathol Med. 2018; 47(5):468-476. DOI: 10.1111/jop.12677. View